Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 05, 2026
Ibotta (IBTA) Gains +13.2% Over 30 Days on Q2 Earnings Strength

Ibotta (IBTA) Gains +13.2% Over 30 Days on Q2 Earnings Strength

Key Takeaways

  • Ibotta (IBTA) shares climbed approximately 13.2% over the last 30 days, propelled by a massive single-day surge following stronger-than-expected Q2 2026 earnings.
  • The company reported revenue of $88.91 million, returning to year-over-year growth for the first time since Q1 2025, and delivered adjusted EBITDA of $16.5 million — 58% above the midpoint of its own guidance.
  • Several analysts raised price targets in the wake of the report, with Wells Fargo lifting its target to $40, Evercore ISI to $42, and Needham reiterating its Buy rating with a $45 target.
  • Despite the rally, insider selling and mixed segment performance — including a 24% drop in direct-to-consumer redemption revenue — continue to divide analyst opinion, with the consensus rating remaining at "Reduce."
  • Management guided Q3 revenue to $86–$90 million, above analyst estimates, and raised its full-year free cash flow target to approximately 70% of adjusted EBITDA.
  • Over the broader quarter, IBTA's price has been nearly flat, underscoring how concentrated the recent move has been around the earnings event.

Ibotta's Business Model and Market Position

Ibotta, Inc. operates a Denver-based performance marketing platform that links consumer packaged goods brands with shoppers through its Ibotta Performance Network. The company, founded in 2012, lets users earn cash-back on purchases ranging from groceries to travel via its app and browser tools. Brands pay only for results through integrations with major retailers and platforms. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Partnerships with names like Walmart and Uber Eats give it a unique spot in ad-tech and retail media, and metrics around redemptions and publisher growth provide investors with timely signals on CPG spending trends.

IBTA Stock Performance: 30 Days Versus the Full Quarter

From a July 6, 2026 close of $33.00 to $37.34 on August 4, 2026, IBTA advanced roughly 13.2%. The move included sharp swings, with a steady decline through late July that bottomed at $24.00 before a 51.9% single-day jump on the earnings release. Over the full three-month period the stock stayed nearly flat at around +0.9%, starting near $37 in early May, dropping sharply mid-quarter, and recovering to end close to where it began. This pattern shows how much the near-term direction depends on quarterly results and guidance updates.

Factors Behind the 30-Day Move in IBTA

The main driver was the Q2 2026 earnings report released August 3. Revenue reached $88.91 million, up 3.3% year over year and the first growth quarter since Q1 2025, beating estimates by about 4.7%. Adjusted EBITDA of $16.5 million exceeded the $10.5 million guidance midpoint and consensus by a wide margin. Adjusted EPS of $0.46 also topped the $0.37 estimate. Third-party publisher revenue rose 27% to $61.5 million while total redeemers increased 21% to 20.9 million. Q3 guidance of $86–$90 million came in above the $85.7 million consensus. I reviewed the earnings details alongside Tickeron’s AI Trend Prediction Engine to gauge momentum signals. Analyst responses followed quickly: Wells Fargo raised its target to $40, Evercore ISI to $42, and Needham kept a Buy rating at $45. Goldman Sachs lifted its target to $32 while keeping a Sell rating. The stock surged 51.9% that day. Offsetting factors included insider sales of roughly 613,000 shares worth $18.7 million in the prior 90 days and a 24% drop in direct-to-consumer redemption revenue.

IBTA's Performance Across the Broader Quarter

Over three months the stock reflected tension between improving fundamentals and ongoing doubts. Shares started near $37 in May, then fell through June and July amid concerns over flat top-line results, negative margins, and questions about publisher growth sustainability. A large insider sale in early July added to the pressure. Revenue per redemption slipped 4% to $0.88 even as user numbers rose. The Q2 report shifted the story by showing 27% growth in third-party publisher revenue and renewed year-over-year growth in most enterprise accounts. The quarter traced a sharp V-shape, highlighting how binary market reactions have become around earnings and the durability of the turnaround.

Key Items to Watch for IBTA Going Forward

Several developments will likely influence the stock next. The 7-Eleven rollout across more than 11,500 U.S. locations in the second half of 2026 could lift redemption volumes and publisher revenue. A next-generation product suite planned for 2027 offers another potential catalyst. Investors will want to track whether mid-single-digit revenue growth holds and whether adjusted EBITDA margins stabilize after the expected Q3 compression toward 15%. Broader economic sensitivity in CPG ad budgets remains a risk, as does the ongoing decline in direct-to-consumer and ad revenue streams. With the consensus rating still at "Reduce" and price targets spanning $22 to $45, upcoming quarters will test whether the August move marks a lasting shift or a one-off reaction.

AI-Powered Trading Approaches with Tickeron

When analyzing names like IBTA, I often review Tickeron’s Trending AI Robots for algorithmic ideas. The page highlights top-performing bots across strategies with transparent metrics, win rates, and trade details, making it straightforward to match approaches to specific trading goals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBTA

IBTA's RSI Oscillator penetrates overbought territory

The RSI Oscillator for IBTA moved into overbought territory on August 04, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for IBTA crossed bearishly below the 50-day moving average on July 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBTA broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBTA entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 27 cases where IBTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on IBTA as a result. In of 43 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBTA just turned positive on August 04, 2026. Looking at past instances where IBTA's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .

IBTA moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where IBTA advanced for three days, in of 134 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.597) is normal, around the industry mean (76.065). IBTA has a moderately high P/E Ratio (307.083) as compared to the industry average of (81.727). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.688). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (2.834) is also within normal values, averaging (52.041).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Zoom Communications Inc (NASDAQ:ZM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 11.68B. The market cap for tickers in the group ranges from 291 to 400.64B. QH holds the highest valuation in this group at 400.64B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 3%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 8%. IDAI experienced the highest price growth at 47%, while YAAS experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 7%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 58
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
IBTA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Industry
N/A
Address
1801 California Street
Phone
+1 303 593-1633
Employees
815
Web
https://www.home.ibotta.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.